Rani Therapeutics Holdings (RANI) Short term Debt (2020 - 2025)
Rani Therapeutics Holdings (RANI) posted quarterly Short term Debt of $13.5 million for Q3 2025, down 8.34% year-over-year from $14.8 million in Q3 2024, and down 9.75% quarter-over-quarter from $15.0 million in Q2 2025.
Rani Therapeutics Holdings (RANI) Short term Debt (2020 - 2025) Analysis & Trends
Rani Therapeutics Holdings' Short term Debt history runs 6 years deep, the most recent figure standing at $13.5 million for Q3 2025.
- In Q3 2025, Short term Debt fell 8.34% year-over-year to $13.5 million; the TTM figure through Sep 2025 stood at $13.5 million (down 8.34% YoY), while the FY2024 annual figure was $15.0 million, up 206.31% from the prior year.
- Short term Debt for Q3 2025 stood at $13.5 million, down from $15.0 million in the prior quarter.
- The five-year high for Short term Debt was $15.0 million in Q4 2024, with the low at $30000.0 in Q2 2022.
- The 5-year median for Short term Debt is $4.9 million (2023), against an average of $7.0 million.
- The sharpest annual moves came in 2022 and 2023: Short term Debt tumbled 99.23% in 2022, then jumped 2121.82% in 2023.
- Rani Therapeutics Holdings' Short term Debt stood at $126000.0 in 2021, then sank by 56.35% to $55000.0 in 2022, then surged by 8803.64% to $4.9 million in 2023, then surged by 206.31% to $15.0 million in 2024, then decreased by 9.75% to $13.5 million in 2025.
- Business Quant data shows RANI's Short term Debt at $13.5 million in Q3 2025, $15.0 million in Q2 2025, and $15.0 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.87 Bn | 78.87 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.40 Bn | 60.22 Bn | 1.37 Bn |
| 4 | Moderna | 59.36 Bn | 54.22 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.91 Bn | 28.60 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.17 Bn | 9.78 Bn | 668.28 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Rani Therapeutics Holdings | 164.41 Mn | 164.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 13.54 Mn |
| Jun 30, 2025 | 15.00 Mn |
| Mar 31, 2025 | 15.00 Mn |
| Dec 31, 2024 | 15.00 Mn |
| Sep 30, 2024 | 14.77 Mn |
| Jun 30, 2024 | 12.29 Mn |
| Mar 31, 2024 | 8.59 Mn |
| Dec 31, 2023 | 4.90 Mn |
| Sep 30, 2023 | 1.22 Mn |
| Sep 30, 2022 | 55,000.00 |
| Jun 30, 2022 | 30,000.00 |
| Mar 31, 2022 | 140,000.00 |
| Dec 31, 2021 | 126,000.00 |
| Sep 30, 2021 | 290,000.00 |
| Jun 30, 2021 | 3.88 Mn |
| Dec 31, 2020 | 145,000.00 |